
    
      In this study, a multicenter, randomized, double-blind, controlled trial design was used to
      compare the efficacy and safety of A140 or Erbitux combined with mfolfox6 regimen in the
      first-line treatment of Ras wild-type metastatic colorectal cancer patients

      Objective to compare the 12 week objective response rate (ORR) of A140 and ebitur combined
      with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal
      cancer.
    
  